Exposure‐safety and exposure‐efficacy analyses for tisotumab vedotin for patients with locally advanced or metastatic solid tumors

• Κύριοι συγγραφείς: Chaitali Passey (Συγγραφέας), Jenna Voellinger (Συγγραφέας), Leonid Gibiansky (Συγγραφέας), Rudy Gunawan (Συγγραφέας), Leonardo Nicacio (Συγγραφέας), Ibrahima Soumaoro (Συγγραφέας), William D. Hanley (Συγγραφέας), Helen Winter (Συγγραφέας), Manish Gupta (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Wiley, 2023-09-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Abstract The antibody‐drug conjugate (ADC) tisotumab vedotin (TV) received accelerated approval from the US Food and Drug Administration for treatment of adults with recurrent or metastatic cervical cancer (r/mCC) with disease progression on or after chemotherapy. A population pharmacokinetic (PK) m...